Beclomethasone (oral inhalation): Drug information

(For additional information see "Beclomethasone (oral inhalation): Patient drug information" and see "Beclomethasone (oral inhalation): Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)

Brand Names: US

Qvar RediHaler

Brand Names: Canada

Qvar

Pharmacologic Category

Corticosteroid, Inhalant (Oral)

Dosing: Adult

Asthma, maintenance/controller

Asthma, maintenance/controller: Oral inhalation: Note: Product selection: Individualize daily beclomethasone dose based on severity of symptoms, typically as follows: Low doses for mild persistent asthma; low to medium doses for moderate persistent asthma; and medium to high doses for severe persistent asthma. Select a product with a favorable dosage per actuation to improve convenience and adherence (Ref).

**Dosage Classification for Beclomethasone Preparations** **(Ref)**
	Low dose	Medium dose	High dose
Beclomethasone	100 to 200 mcg/day	>200 to 400 mcg/day	>400 mcg/day

US labeling: Metered-dose inhaler:

QVAR RediHaler: Note: Dosing based on previous asthma therapy and asthma severity. May increase dose after 2 weeks of therapy in patients who are not adequately controlled.

Patients not currently on inhaled corticosteroids: Oral inhalation: Initial: 40 to 80 mcg twice daily; maximum dose: 320 mcg twice daily.

Patients previously on inhaled corticosteroids: Oral inhalation: Initial: 40 to 320 mcg twice daily; maximum dose: 320 mcg twice daily.

Canadian labeling: Metered-dose inhaler: QVAR:

Mild asthma: Oral inhalation: 50 to 100 mcg twice daily; maximum dose: 100 mcg twice daily.

Moderate asthma: Oral inhalation: 100 to 250 mcg twice daily; maximum dose: 250 mcg twice daily.

Severe asthma: Oral inhalation: 300 to 400 mcg twice daily; maximum dose: 400 mcg twice daily.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric

(For additional information see "Beclomethasone (oral inhalation): Pediatric drug information")

Note: Doses should be titrated to the lowest effective dose once asthma is controlled.

Asthma

Asthma:

Maintenance therapy:

Manufacturer's labeling: Qvar RediHaler: Oral inhalation: Note: Twice daily doses should be administered approximately 12 hours apart.

Children 4 to 11 years: Initial: 40 mcg twice daily; maximum dose: 80 mcg twice daily.

Children ≥12 years and Adolescents:

No previous inhaled corticosteroids: Initial: 40 to 80 mcg twice daily; maximum dose: 320 mcg twice daily.

Previous inhaled corticosteroid use: Initial: 40 to 160 mcg twice daily; maximum dose: 320 mcg twice daily.

Note: Therapeutic ratio between Qvar Redihaler and other beclomethasone inhalers (eg, CFC formulations; however, none are currently available in US) has not been established.

National Asthma Education and Prevention Program Guidelines (Ref): HFA formulation (Qvar RediHaler): Oral inhalation:

Children 5 to 11 years: Administer in divided doses:

"Low" dose: 80 to 160 mcg/day (40 mcg/puff: 2 to 4 puffs/day or 80 mcg/puff: 1 to 2 puffs/day).

"Medium" dose: >160 to 320 mcg/day (40 mcg/puff: 4 to 8 puffs/day or 80 mcg/puff: 2 to 4 puffs/day).

"High" dose: >320 mcg/day (40 mcg/puff: >8 puffs/day or 80 mcg/puff: >4 puff/day).

Children ≥12 years and Adolescents:

"Low" dose: 80 to 240 mcg/day (40 mcg/puff: 2 to 6 puffs/day or 80 mcg/puff: 1 to 3 puffs/day).

"Medium" dose: >240 to 480 mcg/day (40 mcg/puff: 6 to 12 puffs/day or 80 mcg/puff: 3 to 6 puffs/day).

"High" dose: >480 mcg/day (40 mcg/puff: >12 puffs/day or 80 mcg/puff: 6 puffs/day).

Mild flare, exacerbation: Limited data available:

Children ≥12 years and Adolescents with mild to moderate asthma, no prior history of life-threatening asthma exacerbations, and with good self-management skills:

It is recommended to temporarily quadruple the inhaled corticosteroid dose early in the course of a mild flare to decrease the severity of an asthma exacerbation. After symptoms stabilize or after a maximum of 14 days of quadrupled dose, whichever occurs first, patients should be returned to their baseline dose (Ref). Quadrupling the inhaled corticosteroid dose has been shown to decrease the severity of an asthma exacerbation in select patients. In a randomized trial of adolescents ≥16 years and adults (n=1,871), temporarily quadrupling the inhaled corticosteroid dose when asthma control began to deteriorate resulted in fewer severe asthma exacerbations (ie, less treatment with systemic glucocorticoids or unscheduled appointments for asthma) compared to patients who maintained their inhaled corticosteroid dose (Ref). No data for quadrupling the dose in patients <16 years of age has been published. Quintupling the dose of inhaled corticosteroids (fluticasone) in children 5 to 11 years of age was not shown to reduce the rate of severe exacerbations and may have been associated adverse effects (decreased linear growth, particularly in patients <8 years of age) (Ref).

Conversion from oral systemic corticosteroid to orally-inhaled corticosteroid: Initiation of oral inhalation therapy in patients on oral corticosteroids (OCS) should include a gradual dose reduction of OCS. If adrenal insufficiency occurs, temporarily increase the OCS dose and follow with a more gradual withdrawal. Note: When transitioning from systemic to inhaled corticosteroids, supplemental systemic corticosteroid therapy may be necessary during periods of stress or during severe asthma attacks.

Canadian labeling: Maintenance therapy: Metered-dose inhaler: Oral inhalation:

Children 5 to 11 years: Initial: 50 mcg twice daily; maximum dose: 100 mcg twice daily.

Children ≥12 years of age and Adolescents:

Mild asthma: 50 to 100 mcg twice daily; maximum dose: 100 mcg twice daily.

Moderate asthma: 100 to 250 mcg twice daily; maximum dose: 250 mcg twice daily.

Severe asthma: 300 to 400 mcg twice daily; maximum dose: 400 mcg twice daily.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

>10%:

Central nervous system: Headache (1% to 25%)

Respiratory: Pharyngitis (3% to 27%)

1% to 10%:

Central nervous system: Pain (1% to 5%), voice disorder (4%)

Gastrointestinal: Oral candidiasis (1% to 8%), vomiting (children: 3%), diarrhea (children: 1% to 3%), nausea (1% to 3%)

Genitourinary: Dysmenorrhea (1% to 3%), viral gastroenteritis (children: 1% to 3%)

Infection: Influenza (children: 1% to 3%)

Neuromuscular & skeletal: Back pain (1% to 4%), myalgia (children: 1% to 3%)

Otic: Otitis (children: 1% to 3%)

Respiratory: Nasopharyngitis (2% to 9%), upper respiratory tract infection (3% to 8%), cough (1% to 7%), viral upper respiratory tract infection (2% to 4%), oropharyngeal pain (1% to 4%), sinusitis (3%), allergic rhinitis (≤3%)

Miscellaneous: Fever (children: 3%)

<1%, postmarketing, and/or case reports: Aggressive behavior, blurred vision, depression, dysgeusia (Tuccori 2011), psychomotor agitation, retinopathy, sleep disorder, suicidal ideation

Contraindications

Hypersensitivity to beclomethasone or any component of the formulation; status asthmaticus, or other acute asthma episodes requiring intensive measures

Canadian labeling: Additional contraindications (not in US labeling): Moderate to severe bronchiectasis requiring intensive measures; untreated fungal, bacterial, or tubercular infections of the respiratory tract

Warnings/Precautions

Concerns related to adverse effects:

• Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Adult patients receiving ≥20 mg per day of prednisone (or equivalent) may be most susceptible. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do not provide the systemic steroid needed to treat patients having trauma, surgery, or infections (particularly gastroenteritis), or other conditions with severe electrolyte loss. Select surgical patients on long-term, high-dose, inhaled corticosteroid should be given stress doses of hydrocortisone intravenously during the surgical period and the dose reduced rapidly within 24 hours after surgery (NAEPP 2007).

• Bronchospasm: Paradoxical bronchospasm that may be life-threatening may occur with use of inhaled bronchodilating agents; reaction should be distinguished from inadequate response. If paradoxical bronchospasm occurs, discontinue beclomethasone and institute alternative therapy.

• Hypersensitivity reactions: Hypersensitivity reactions (eg, angioedema, bronchospasm, rash, and urticaria) may occur; discontinue use if reaction occurs.

• Immunosuppression: Prolonged use of corticosteroids may increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Avoid use, if possible, in patients with ocular herpes, respiratory tuberculosis (TB) disease (active TB) or TB infection (latent TB), or untreated viral, fungal, parasitic or bacterial systemic infections. Exposure to chickenpox and measles should be avoided; if the patient is exposed, prophylaxis with varicella zoster immune globulin or pooled intramuscular immunoglobulin, respectively, may be indicated; if chickenpox develops, treatment with antiviral agents may be considered.

• Oral candidiasis: Local oropharyngeal Candida albicans infections have been reported; if this occurs, treat appropriately while continuing therapy. Patients should be instructed to rinse mouth with water without swallowing after each use.

Disease-related concerns:

• Asthma: Appropriate use: Supplemental steroids (oral or parenteral) may be needed during stress or severe asthma attacks. Use is contraindicated in status asthmaticus or during other acute episodes of asthma requiring intensive measures.

• Bone mineral density: Use with caution in patients with major risk factors for decreased bone mineral count such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (eg, antiseizure medications, oral corticosteroids); long-term use of inhaled corticosteroids have been associated with decreases in bone mineral density.

• Ocular disease: Use with caution in patients with cataracts and/or glaucoma; blurred vision, increased intraocular pressure, glaucoma, and cataracts have occurred with prolonged use. Consider routine eye exams in chronic users.

Special populations:

• Pediatric: Orally inhaled corticosteroids may cause a reduction in growth velocity in pediatric patients (~1 centimeter per year [range: 0.3 to 1.8 cm per year] and related to dose and duration of exposure). To minimize the systemic effects of orally inhaled corticosteroids, each patient should be titrated to the lowest effective dose. Growth should be routinely monitored in pediatric patients.

Other warnings/precautions:

• Discontinuation of therapy: A gradual tapering of dose may be required prior to discontinuing therapy; there have been reports of systemic corticosteroid withdrawal symptoms (eg, joint/muscle pain, lassitude, depression) when withdrawing oral inhalation therapy.

• Transfer to oral inhaler: When transferring to oral inhalation therapy from systemic corticosteroid therapy, previously suppressed allergic conditions (rhinitis, conjunctivitis, eczema, arthritis, and eosinophilic conditions) may be unmasked. Withdraw systemic corticosteroid therapy by gradually tapering the dose. Monitor lung function, beta-agonist use, asthma symptoms, and for signs and symptoms of adrenal insufficiency (eg, fatigue, lassitude, weakness, nausea/vomiting, hypotension) during withdrawal.

Warnings: Additional Pediatric Considerations

Reduction in growth velocity may occur when corticosteroids are administered to pediatric patients, even at recommended doses via inhaled route; reduction in growth velocity is related to dose and duration of exposure; monitor growth. With beclomethasone-HFA (Qvar), the mean reduction in growth velocity was 0.5 cm/year less than that with the previous beclomethasone CFC inhaler formulation. Use of Qvar with a spacer device is not recommended in children <5 years of age due to the decreased amount of medication that is delivered with increasing wait times; patients should be instructed to inhale immediately if using a spacer device.

Although recommended in children ≥12 years and adolescents, using higher doses (quintupled) in children <12 years of age has not shown efficacy and may be associated with a higher risk of adverse effects. A study in children 5 to 11 years of age with mild to moderate persistent asthma evaluated quintupling the dose of the inhaled corticosteroid (fluticasone) following the early signs of decreased asthma control; results showed that quintupled fluticasone dosages did not reduce the rate of severe exacerbations and may have been associated adverse effects (decreased linear growth, particularly in patients <8 years of age) (Jackson 2018).

Dosage Forms Considerations

Qvar Redihaler 10.6 g canisters contain 120 inhalations.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Aerosol Breath Activated, Inhalation, as dipropionate:

Qvar RediHaler: 40 mcg/actuation (10.6 g); 80 mcg/actuation (10.6 g)

Generic Equivalent Available: US

Pricing: US

Aerosol (Qvar RediHaler Inhalation)

40 mcg/ACT (per gram): $24.19

80 mcg/ACT (per gram): $32.39

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Aerosol Solution, Inhalation, as dipropionate:

Qvar: 50 mcg/actuation (12.4 g); 100 mcg/actuation (12.4 g)

Administration: Adult

Oral inhalation: Metered-dose inhaler: Do not shake prior to use. Avoid spraying in face or eyes. Rinse mouth with water (without swallowing) after each use. Do not wash or put inhaler in water; mouth piece may be cleaned with a dry tissue or cloth. Discard the inhaler when the dose counter displays "0".

QVAR [Canadian product]: Prime inhaler by spraying four test sprays prior to initial use or if not in use for >14 days.

QVAR RediHaler: Inhaler device is breath-actuated; does not require priming before use. The white cap on the inhaler must remain closed during storage; do not open white cap until ready for use. If more than 1 inhalation is needed per dose, make sure the white cap is closed prior to next inhalation. If the white cap has been opened for >2 minutes or left in the open position, close the white cap to prepare inhaler and check dose counter to make sure the inhaler is not empty. Never breathe out into the inhaler mouthpiece. Do not use with a spacer or volume-holding chamber.

Administration: Pediatric

Oral inhalation: Do not shake prior to use. Avoid spraying in face or eyes. Rinse mouth with water (without swallowing) after each use to prevent Candida infection. Do not wash or put inhaler in water; mouthpiece may be cleaned with a dry tissue or cloth. Discard the inhaler when the dose counter displays "0" even if container is not completely empty.

Qvar RediHaler: Inhaler device is breath-actuated; does not require priming before use. It is not necessary to shake before use. The white cap on the inhaler must remain closed during storage; do not open white cap until ready for use. While grasping inhaler for dose inhalation, ensure fingers do not cover the top of device (vent area). If more than 1 inhalation is needed per dose, make sure the white cap is closed prior to next inhalation. If the white cap has been opened for >2 minutes or left in the open position, close the white cap to prepare inhaler and check dose counter to make sure the inhaler is not empty. Never breathe out into the inhaler mouthpiece. Do not use with a spacer or volume-holding chamber.

Qvar, metered dose inhaler: Canister does not need to be shaken prior to use. Prime canister by spraying twice into the air prior to initial use or if not in use for >10 days. Avoid spraying in face or eyes. Exhale fully prior to bringing inhaler to mouth. Place inhaler in mouth, close lips around mouthpiece, and inhale slowly and deeply while pressing down on the canister with your finger. Remove inhaler and hold breath for approximately 5 to 10 seconds.

Use: Labeled Indications

Asthma, maintenance/controller: Maintenance and prophylactic treatment of asthma in patients ≥5 years of age (QVAR [Canadian product]) or ≥4 years of age (QVAR RediHaler).

Limitations of use: Not for relief of acute bronchospasm.

Metabolism/Transport Effects

Substrate of CYP3A4 (minor); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Cosyntropin: Corticosteroids (Orally Inhaled) may diminish the diagnostic effect of Cosyntropin. Risk C: Monitor therapy

Desmopressin: Corticosteroids (Orally Inhaled) may enhance the hyponatremic effect of Desmopressin. Risk X: Avoid combination

Loxapine: Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically, the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine. Management: This is specific to the Adasuve brand of loxapine, which is an inhaled formulation. This does not apply to non-inhaled formulations of loxapine. Risk X: Avoid combination

Tobacco (Smoked): May diminish the therapeutic effect of Corticosteroids (Orally Inhaled). Risk C: Monitor therapy

Reproductive Considerations

Uncontrolled asthma may negatively affect fertility by increasing time to pregnancy and reducing birth rate. Fertility may be improved in patients adequately treated with inhaled corticosteroids (Couillard 2021; ERS/TSANZ [Middleton 2020]). Inhaled corticosteroids used for the treatment of asthma should not be discontinued in patients planning to become pregnant (GINA 2023). The lowest dose that maintains asthma control should be continued (ERS/TSANZ [Middleton 2020]).

Pregnancy Considerations

Maternal use of inhaled corticosteroids (ICS) in usual doses is not associated with an increased risk of fetal malformations; a small risk of malformations was observed in one study following maternal doses of beclomethasone >1,000 mcg/day (ERS/TSANZ [Middleton 2020]).

Uncontrolled asthma is associated with adverse events on pregnancy (increased risk of perinatal mortality, preeclampsia, preterm birth, low-birth-weight infants, cesarean delivery, and the development of gestational diabetes). Poorly controlled asthma or asthma exacerbations may have a greater fetal/maternal risk than what is associated with appropriately used asthma medications. Maternal treatment improves pregnancy outcomes by reducing the risk of some adverse events (eg, preterm birth and gestational diabetes) (ERS/TSANZ [Middleton 2020]; GINA 2023).

Inhaled corticosteroids are recommended for the treatment of asthma during pregnancy. Due to the risk of exacerbations, stepping down or stopping ICS should not be done during pregnancy (GINA 2023). Beclomethasone is one of the preferred ICS. The lowest dose that maintains asthma control should be continued (ERS/TSANZ [Middleton 2020]). Maternal asthma symptoms should be monitored monthly during pregnancy (ERS/TSANZ [Middleton 2020]; GINA 2023).

Data collection to monitor pregnancy and infant outcomes associated with asthma and the medications used to treat asthma in pregnancy is ongoing. Health care providers are encouraged to enroll exposed pregnant patients in the MotherToBaby Pregnancy Studies conducted by the Organization of Teratology Information Specialists (OTIS) (1-877-311-8972 or https://mothertobaby.org). Patients may also enroll themselves.

Breastfeeding Considerations

It is not known if beclomethasone is present in breast milk following oral inhalation; however, other inhaled corticosteroids are present in breast milk.

According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.

Beclomethasone oral inhalation is considered compatible with breastfeeding (ERS/TSANZ [Middleton 2020]).

Monitoring Parameters

FEV₁, peak flow, and/or other pulmonary function tests; bone mineral density; growth (adolescents and children via stadiometry); signs/symptoms of HPA axis suppression/adrenal insufficiency; possible eosinophilic conditions (including eosinophilic granulomatosis with polyangiitis [formerly known as Churg-Strauss]), signs/symptoms of oral candidiasis; asthma symptoms; glaucoma/cataracts

Mechanism of Action

Controls the rate of protein synthesis; depresses the migration of polymorphonuclear leukocytes, fibroblasts; reverses capillary permeability and lysosomal stabilization at the cellular level to prevent or control inflammation

Pharmacokinetics (Adult Data Unless Noted)

Onset of action: Within 1 to 2 days in some patients; usually within 1 to 2 weeks; Maximum effect: 3 to 4 weeks

Absorption: Readily; quickly hydrolyzed by pulmonary esterases to active metabolite (beclomethasone-17-monopropionate [17-BMP]) during absorption

Distribution: V_d: Beclomethasone dipropionate (BDP): 20 L; 17-BMP: 424 L

Protein binding: 17-BMP: 94% to 96%

Metabolism: BDP is a pro-drug (inactive); undergoes rapid conversion to 17-BMP during absorption; followed by additional metabolism via CYP3A4 to other, less active metabolites (beclomethasone-21-monopropionate [21-BMP] and beclomethasone [BOH])

Half-life elimination: QVAR RediHaler: 17-BMP: 4 hours

Time to peak, plasma: Inhalation: QVAR RediHaler: BDP: 2 minutes; 17-BMP: 10 minutes

Excretion: Primary route of excretion is via feces; <10% of dose excreted in urine as metabolites

Brand Names: International

International Brand Names by Country

For country code abbreviations (show table)

(AE) United Arab Emirates: Ibicar;
(AR) Argentina: Autobec 100 autohaler | Qvar;
(AU) Australia: Qvar | Respocort;
(BD) Bangladesh: Ascon | Azbec | Beclocort | Beclomin | Steradin;
(BE) Belgium: Qvar;
(BR) Brazil: Ailuk | Clenil | Clenil HFA | Dipropionato de beclometasona;
(CH) Switzerland: Qvar;
(CI) Côte d'Ivoire: Becloject | Cortis;
(CL) Chile: Alart b | Destap sf;
(CO) Colombia: Beclometasona | Beclometasona dipropionato | Beclometasona MK | Beclonose | Beclort | Besone | Ciplametazon;
(CZ) Czech Republic: Beclazone | Ecobec | Soprobec;
(DE) Germany: Aerobec N | Beclo | Beclo Sandoz | Beclobreathe | Beclohexal | Beclometason | Beclometason ct | Beclometason glenmark | Becloturmant | Junik | Qvar | Sanasthmax | Ventolair;
(DO) Dominican Republic: Beclobronc;
(EC) Ecuador: Beclometasona;
(EE) Estonia: Beclometason;
(ES) Spain: Novahaler | Qvar | Soprobec;
(FI) Finland: Aerobec;
(FR) France: Beclojet | Beclometasone Merck | Beclospray | Ecobec | Prolair | Qvar;
(GB) United Kingdom: Aerobec | Beclazone | Becloforte | Becotide | Kelhale | Qvar | Soprobec;
(GR) Greece: Qvar;
(HK) Hong Kong: Beclate | Beclazone;
(IE) Ireland: Beclazone | Becotide | Clenil modulite | Qvar;
(IL) Israel: Qvar;
(IT) Italy: Clenil | Clenil forte jet;
(JP) Japan: Qvar;
(KE) Kenya: Beclate | Besone | Ibicar | Steradin;
(KW) Kuwait: Beclazone | Clenil modulite | Qvar;
(LT) Lithuania: Beclazone | Beclometason;
(LU) Luxembourg: Qvar;
(LV) Latvia: Ecobec;
(MA) Morocco: Aircort | Cortis;
(MX) Mexico: Beclometasona | Clofhiven | Ze Rimsol;
(MY) Malaysia: Arite | Beclate | Beclazone | Biosone | Clenil | Decomit | Ibicar | Qvar | Uni Beclo;
(NL) Netherlands: Aerobec | Beclodin Modulite | Beclometason | Beclometason cf | Beclometason sandoz | Beclometasondipropionaat PCH | Qvar | Soprobec;
(NO) Norway: Aerobec;
(NZ) New Zealand: Qvar | Respocort;
(PE) Peru: Beclometasona | Ibicar;
(PH) Philippines: Clenil | Ibicar | Qvar;
(PL) Poland: Cortare | Soprobec;
(PR) Puerto Rico: Qvar;
(PT) Portugal: Beclometasona Generis | Ecobec easi-breath;
(QA) Qatar: Beclo-Asma | Beclohale | Beclozone | Bekson Forte | Clenil Modulite | Ibicar | Soprobec;
(RO) Romania: Becotide | Ecobec;
(RU) Russian Federation: Beclometasone | Beklazon eco;
(SA) Saudi Arabia: Beclazone | Becloforte | Becotide;
(SE) Sweden: Aerobec;
(SG) Singapore: Beclo Asma;
(SK) Slovakia: Beclazone;
(TH) Thailand: Beclocip;
(TN) Tunisia: Beclojet | Cortis;
(TW) Taiwan: Beclazone;
(UG) Uganda: Ibicar;
(VE) Venezuela, Bolivarian Republic of: Eclosynt;
(ZA) South Africa: Becloflam | Biosone | Qvar;
(ZM) Zambia: Beclazone

Couillard S, Connolly C, Borg C, Pavord I. Asthma in pregnancy: an update. Obstet Med. 2021;14(3):135-144. doi:10.1177/1753495X20965072 [PubMed 34646341]
Global Initiative for Asthma (GINA). GINA report, Global Strategy for Asthma Management and Prevention. https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf. Updated 2019. Accessed December 13, 2019.
Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. https://ginasthma.org/2023-gina-main-report/. Updated 2023. Accessed August 23, 2023.
Goedert JJ, Vitale F, Lauria C, et al, “Risk Factors for Classical Kaposi's Sarcoma,” J Natl Cancer Inst, 2002, 94(22):1712-8. [PubMed 12441327]
Jackson DJ, Bacharier LB, Mauger DT, et al. Quintupling inhaled glucocorticoids to prevent childhood asthma exacerbations. N Engl J Med. 2018;378(10):891-901. [PubMed 29504498]
Lougheed MD, Lemière C, Dell SD, et al, “Canadian Thoracic Society Asthma Management Continuum - 2010 Consensus Summary for Children Six Years of Age and Over, and Adults,” Can Respir J, 2010, 17(1):15-24. [PubMed 20186367]
McKeever T, Mortimer K, Wilson A, et al. Quadrupling inhaled glucocorticoid dose to abort asthma exacerbations. N Engl J Med. 2018;378(10):902-910. doi:10.1056/NEJMoa1714257 [PubMed 29504499]
Middleton PG, Gade EJ, Aguilera C, et al. ERS/TSANZ Task Force statement on the management of reproduction and pregnancy in women with airways diseases. Eur Respir J. 2020;55(2):1901208. doi:10.1183/13993003.01208-2019 [PubMed 31699837]
National Asthma Education and Prevention Program (NAEPP), Expert Panel Report 3. Guidelines for the Diagnosis and Management of Asthma. Clinical Practice Guidelines, National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm
Pedersen S, Warner J, Wahn U, et al. Growth, Systemic Safety, and Efficacy During 1 Year of Asthma Treatment With Different Beclomethasone Dipropionate Formulations: An Open-Label, Randomized Comparison of Extra Fine and Conventional Aerosols in Children. Pediatrics. 2002;109(6). http://www.pediatrics.org/cgi/content/full/109/6/e92. [PubMed 12042586]
Qvar (beclomethasone) [prescribing information]. Frazer, PA: Teva Respiratory, LLC; June 2018.
Qvar Redihaler (beclomethasone dipropionate HFA) [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals USA Inc; September 2022.
QVAR (beclomethasone) [product monograph]. Laval, Quebec, Canada: Bausch Health, Canada Inc; December 2020.
Tinkelman DG, Reed CE, Nelson HS, et al. Aerosol Beclomethasone Dipropionate Compared With Theophylline as Primary Treatment of Chronic, Mild-to-Moderately Severe Asthma in Children. Pediatrics. 1993;92(1):64-77. [PubMed 8516087]
Todd GR, Acerini CL, Buck JJ, et al. Acute Adrenal Crisis in Asthmatics Treated With High-Dose Fluticasone Propionate. Eur Respir J. 2002;19(6):1207-9. [PubMed 12108877]
Todd GR, Acerini CL, Ross-Russell R, et al. Survey of Adrenal Crisis Associated With Inhaled Corticosteroids in the United Kingdom. Arch Dis Child. 2002;87(6):457-461. [PubMed 12456538]
Tuccori M, Lapi F, Testi A, et al. Drug-induced taste and smell alterations: a case/non-case evaluation of an italian database of spontaneous adverse drug reaction reporting. Drug Saf. 2011;34(10):849-859. [PubMed 21879779]
Wyatt R, Waschek J, Weinberger M, et al. Effects of Inhaled Beclomethasone Dipropionate and Alternate-Day Prednisone on Pituitary-Adrenal Function in Children With Chronic Asthma. N Engl J Med. 1978;299(25):1387-1792. [PubMed 362207]

Topic 8876 Version 272.0

خرید پکیج

Beclomethasone (oral inhalation): Drug information